Outlook 2017

Barring unforeseen circumstances

The Straumann Group expects the global implant market to grow at a similar rate (3-4%) in 2017. Thanks to the strong performance so far this year, the Group is raising its full-year guidance for organic growth to the low double-digit percentage range. Despite further investments in strategic growth initiatives and assuming that currency exchange rates remain fairly stable, the expected revenue growth and operational leverage should lead to further improvements in the (organic1) operating profit margin (2016: 24.8%).

1 Excluding the effects of the Medentika and the Equinox consolidation/acquisition and currencies.

Previous Guidance (February 2017)

The Straumann Group expects the global implant market to grow at a similar rate (3-4%) in 2017 and is confident that it can continue to outperform by achieving organic revenue growth in the high-single-digit range. Despite further investments in strategic growth initiatives and assuming that currency exchange rates remain fairly stable, the expected revenue growth and operational leverage should lead to further improvements in the (organic1) operating profit margin.